Medicine Needs Its Tesla Moment

In the treatment of type 2 diabetes, we have made extraordinary advances in pharmacotherapy. New medications lower blood glucose, reduce cardiovascular risk and even promote weight loss. And yet, despite this progress, the disease continues to spread—affecting more than 37 million Americans—and for most patients, it remains relentlessly progressive.

We have become remarkably good at managing diabetes. We have not learned how to stop it.

The problem is not a lack of innovation. It is that we are innovating within a system built on a flawed premise: that type 2 diabetes is best treated by correcting blood sugar rather than addressing its root cause.

From a physiological standpoint, type 2 diabetes is not a medication deficiency. It is a disease of insulin resistance, driven in large part by the accumulation of fat within the liver and muscle cells — what researchers refer to as ectopic fat. This intracellular fat disrupts insulin signaling, impairing the body’s ability to regulate glucose effectively, a mechanism demonstrated in seminal work by Taylor et al.

When the underlying cause is addressed, the biology changes—often rapidly.

A growing body of clinical research shows that targeted dietary interventions, particularly those centered on plant-based foods, can reduce ectopic fat, improve insulin sensitivity and, in many cases, lead to remission of type 2 diabetes. These are not marginal effects but clinically meaningful outcomes observed in randomized trials and real-world settings, including works my colleagues and I have published.

Yet this approach remains peripheral to mainstream care.

Why? Because our health care system, like the pre-Tesla auto industry, is optimized for incremental improvement, not systemic redesign. Clinical workflows prioritize prescriptions over prevention. Reimbursement models reward procedures and pharmacotherapy more than sustained lifestyle support. And perhaps most limiting of all, we have quietly accepted the belief that patients cannot or will not change.

But that belief reflects a failure of systems, not of people.

When patients are given clear, evidence-based guidance, structured support and a framework that aligns with human biology rather than fighting against it, change is not only possible—it is common. In clinical trials and practice alike, patients routinely achieve improvements that were once considered unrealistic.

The question is not whether nutrition can play a central role in treating metabolic disease. The science is increasingly clear that it can. The question is whether we are willing to rethink the system that delivers care.

Every industry reaches a point where incremental progress is no longer enough. In transportation, that moment produced Tesla. In media, it produced streaming. In health care, that moment is now.

We can continue refining a model that manages disease more efficiently. Or we can build one that restores health.

The future of medicine will not be defined by how well we control chronic illness. It will be defined by how often we reverse it.